From: Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
All patients (n = 98) | Remissiona (n = 76) | Active diseasea (n = 22) | |
---|---|---|---|
Age, years, median (range) | 53 (19–85) | 68 (24–84) | 63 (19–85) |
Disease duration, years, median (range) | 6 (0–50) | 7 (0–50) | 0.5 (0–25) |
GPA, %, (n) | 76 (74) | 74 (56) | 82 (18) |
MPA, %, (n) | 24 (24) | 26 (20) | 18 (4) |
PR3-ANCA, %, (n) | 63 (62) | 61 (46) | 73 (16) |
MPO-ANCA, %, (n) | 30 (30) | 32 (24) | 27 (6) |
ANCA negativeb | 5 (5) | 5 (4) | 0 (0) |
BVAS3, median (range) | 0 (0–16) | 0 (0–0) | 5 (1–16) |
Leukocytes, 109/L, median (range)c | 6.4 (3–13.7) | 6.2 (3.2–13.7) | 7.9 (3–12) |
p-creatinine, μmol/L, median (range) | 103 (54–805) | 98 (61–635) | 154 (54–805) |
p-CRP, mg/L, median (range) | 2.9 (< 0.6–92) | 2.6 (< 0.6–27) | 5.7 (< 0.6–92) |
Treatment | |||
Prednisone, %, median dose of treated | 59 (6.25 mg/d) | 53 (5 mg/d) | 82 (17.5 mg/d) |
Azathioprine, % (n) | 28 (27) | 32 (24) | 14 (3) |
Mycophenolate, % (n) | 8 (8) | 11 (8) | 0 (0) |
Rituximab, % (n) | 20 (20) | 21 (16) | 18 (4) |
Methotrexate, % (n) | 14 (14) | 13 (10) | 18 (4) |
Cyklophosphamide, % (n) | 13 (13) | 7 (5) | 36 (8) |
No current treatment, % (n) | 12 (12) | 14 (11) | 9 (3) |